Literature DB >> 1978988

Differential cross-tolerance between intrathecal morphine and sufentanil in the rat.

M Sosnowski1, T L Yaksh.   

Abstract

By means of a subcutaneously implanted osmotic pump, groups of rats received a constant-rate (1 microliter/h), 7-day intrathecal infusion of saline or one of two mu opioid agonists: sufentanil (0.6 nmol/h) or morphine (20 nmol/h). These concentrations of morphine and sufentanil yielded a comparable near maximal hot-plate response latency on day 1 of the infusion. On day 7, the magnitude of tolerance was assessed in each group by establishing intrathecal dose-response curves and ED50 values for sufentanil and morphine given as a bolus injection. Each infused animal was used for a single bolus injection. In all cases, infusion with the opioid resulted in a rightward shift (increase in ED50) for both morphine and sufentanil as compared to saline-infused animals. The magnitude of the shift, however, was different for the two drugs. Thus in morphine-infused rats, the morphine ED50 increased as compared to saline-infused animals by a factor of 44, whereas the sufentanil ED50 shifted by a factor of 10. In sufentanil-infused animals, the respective shifts in the morphine and sufentanil ED50 values were increased by a factor of 9 and 3, respectively. Thus, a significantly greater shift as compared to saline-infused animals was observed in morphine-infused than in sufentanil-infused animals. Conversely, regardless of the opioid to which the animal was exposed, morphine-tested animals showed a greater rightward shift than did sufentanil-tested animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978988     DOI: 10.1097/00000542-199012000-00012

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  Pain management in the critically ill child.

Authors:  M Yaster; D G Nichols
Journal:  Indian J Pediatr       Date:  2001-08       Impact factor: 1.967

Review 2.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Chronic ethanol consumption in rats produces opioid antinociceptive tolerance through inhibition of mu opioid receptor endocytosis.

Authors:  Li He; Jennifer L Whistler
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

Review 4.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

5.  Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil.

Authors:  D A Lytle; M W Emmett-Oglesby; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 6.  Pain management: physiopathology, future research and endpoints.

Authors:  M Sosnowski
Journal:  Support Care Cancer       Date:  1993-03       Impact factor: 3.603

7.  Analgesic tolerance to microinjection of the micro-opioid agonist DAMGO into the ventrolateral periaqueductal gray.

Authors:  Paul J Meyer; Erin N Fossum; Susan L Ingram; Michael M Morgan
Journal:  Neuropharmacology       Date:  2007-03-12       Impact factor: 5.250

Review 8.  Relevance of Mu-Opioid Receptor Splice Variants and Plasticity of Their Signaling Sequelae to Opioid Analgesic Tolerance.

Authors:  Sumita Chakrabarti; Nai-Jiang Liu; Alan R Gintzler
Journal:  Cell Mol Neurobiol       Date:  2020-08-17       Impact factor: 5.046

9.  Malfunctioning sufentanil intrathecal pain pump: a case report.

Authors:  Lindsay Warner; Anna Branstad; Lindsay Hunter Guevara; Laura Matzke Bitterman; Matthew Pingree; Wayne Nicholson; Jason Eldrige
Journal:  J Med Case Rep       Date:  2020-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.